When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...

Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth $11. ...

Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth ...

Novo Nordisk will soon acquire from Novo Holdings Catalent’s three fill-finish sites located in Italy, the U.S., and Belgium.

the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab, as the Danish drugmaker looks to boost ...

The parent company of Danish drug maker Novo Nordisk said it completed its $16.5 billion purchase of Catalent, including the Bloomington operations on Wednesday. Here’s what you need to know.

Novo Nordisk to invest $1.2 billion in Denmark for a new production site, creating 400 permanent jobs by 2027. Novo Holdings completes Catalent acquisition despite opposition, impacting Novo ...

The Danish investment company Novo Nordisk A/S has received approval from the US Federal Trade Commission (FTC) to acquire the production assets of Catalent Inc., one of the world's largest ...